Trump Says he Could Override FDA Vaccine Standards

US president Donald Trump has said he believes the White House could override the US Food and Drug Administration (FDA) if the national health watchdog goes ahead with mooted plans to toughen standards for approval of a Covid-19 vaccine or an Emergency Use Authorization.

“We're looking at that and that has to be approved by the White House,” Trump said, adding that it “sounds like a political move.” The president is said to believe that a pre-election authorization would translate into a victory for him. He has repeatedly promised that a vaccine would be ready by election day, which is Nov. 3.

While The FDA declined to comment on Trump's remarks, an FDA spokesperson told news broadcaster CNN that the agency’s guidelines must go through White House Office of Management and Budget review process.

Rumors of a move by the health agency to reassure the American public and the worried National Institutes of Health (NIH) that the first vaccines to be approved by the FDA will be safe surfaced earlier this week and speculation focused on tougher guidelines being  announced later in the week.

Without giving any details, FDA commissioner Stephen Hahn told the US Senate Health Committee on Sept. 23 that the "FDA will not authorize or approve a vaccine that we would not feel comfortable giving to our families.” It would have to meet the agency's “rigorous expectations” for safety and effectiveness, he said.

Hahn has come under fire from some in the health sector for repeatedly obliging the president’s requests for EUAs that many were skeptical about.

Peter Hotez, a vaccinologist at Baylor College of Medicine in Texas, told the broadcaster

he was concerned that “there could be a gray zone where a vaccine looks partially protective and it goes on the market without a full formal review process.”

US president Donald Trump thinks he could override any tougher standards the...
US president Donald Trump thinks he could override any tougher standards the Food and Drug Administration (FDA) could require for approving a Covid-19 vaccine or an Emergency Use Authorization (EUA). The president has promised voters a vaccine before the Nov. 3 election. (c) @realDonaldTrump

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.